| Biomarker ID | 817 |
| PMID | 22126577 |
| Year | 2011 |
| Biomarker | Interleukin-18 (IL-18) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Interleukin-27-mediated signaling events,Interleukin-23-mediated signaling events,Corticotropin releasing hormone pathway,Cytokines and inflammatory response,Interleukin-12/STAT4 pathway |
| Experiment | Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage |
| Type of Biomarker | Prognostic |
| Cohort | Of a total of 149 patients, 71 had biopsy proven prostate cancers (TNM stage: T2=17, T3=26 and T4=28) and 78 clinical benign prostate hyperplasia (BPH).71 age matched controls were also selected |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IL18 |